Disease · MONDO_0005723

Cryptococcal meningitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Cryptococcal meningitis. Diseases, record MONDO_0005723. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005723

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Cryptococcal meningitis; Open Targets
Open Targets ID: MONDO_0005723; Open Targets
Other names: Cryptococcal meningitis (disorder), Cryptococcus neoformans caused infectious meningitis, Cryptococcus neoformans infectious meningitis, Meningitis, Cryptococcal; Open Targets
Disease Ontology: DOID:0080159; Disease Ontology
MeSH: D016919; MeSH
NCI Thesaurus: C174113; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 15 drugs, from DailyMed and PMDA; Open Targets

Drugs15

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AMPHOTERICIN B	CHEMBL267345	Small molecule	Approval	DailyMed	22	21	20	Drugs and targets
FLUCONAZOLE	CHEMBL106	Small molecule	Approval	DailyMed	99	20	20	Drugs and targets
ISAVUCONAZONIUM SULFATE	CHEMBL3137333	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
FLUCYTOSINE	CHEMBL1463	Small molecule	Phase 3	ClinicalTrials.gov	14	14	14	Drugs and targets
SERTRALINE	CHEMBL809	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
OTESECONAZOLE	CHEMBL3311228	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
EFUNGUMAB	CHEMBL1743009	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ITRACONAZOLE	CHEMBL64391	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
INTERFERON GAMMA-1B	CHEMBL1201564	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TAMOXIFEN	CHEMBL83	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 15

See all 15 drugs

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
BDKRB2	B2 bradykinin receptor	1	Bradykinin B2 receptor agonist	Phase 1	https://conductscience.org/library/genes/624	Drugs and targets
ESR1	Estrogen receptor	1	Estrogen receptor alpha modulator	Phase 2	https://conductscience.org/library/genes/2099	Drugs and targets
IFNGR1	Interferon gamma receptor	1	Interferon gamma receptor agonist	Phase 2	https://conductscience.org/library/genes/3459	Drugs and targets
IFNGR2	Interferon gamma receptor	1	Interferon gamma receptor agonist	Phase 2	https://conductscience.org/library/genes/3460	Drugs and targets
SLC6A4	Sodium-dependent serotonin transporter	1	Serotonin transporter inhibitor	Phase 3	https://conductscience.org/library/genes/6532	Drugs and targets

Trials34

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01802385	Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis	Phase 3	460	2020-01-13	Cryptococcal Meningitis, Fungal Meningitis	SERTRALINE	Its record names the disease	ClinicalTrials.gov
NCT00885703	High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals	Phase 1/2	168	2018-03-12	Cryptococcal Meningitis, HIV Infections	AMPHOTERICIN B, FLUCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00145249	Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis	Phase 2	143	2010-06-23	Cryptococcal Meningitis	AMPHOTERICIN B, FLUCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT06414512	Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis	Phase 2	48	2025-08-27	Cryptococcal Meningitis	FLUCYTOSINE	Its record names the disease	ClinicalTrials.gov
NCT01562132	Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection	Phase 2	6	2015-08-31	Cryptococcal Infection Disseminated	FLUCONAZOLE, FLUCYTOSINE	Its record names the disease	ClinicalTrials.gov
NCT06666322	Platform Trial For Cryptococcal Meningitis (PLATFORM-CM)	Phase 2/3	2,000		Hiv, Cryptococcal Meningitis	OTESECONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00000639	A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis	Not applicable	400		Meningitis, Cryptococcal, HIV Infections	AMPHOTERICIN B, FLUCONAZOLE, FLUCYTOSINE, ITRACONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03945448	Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia	Phase 2/3	356		Cryptococcal Meningitis	AMPHOTERICIN B, FLUCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00001017	Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS	Phase 3	330		Meningitis, Cryptococcal, HIV Infections	AMPHOTERICIN B, FLUCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT05541107	Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3	Phase 3	270		Cryptococcal Meningitis	AMPHOTERICIN B	Its record names the disease	ClinicalTrials.gov

1 to 10 of 34

See all 34 trials

Comparisons in its trials12

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Sertraline 400mg vs Placebo: Number of Participants Experiencing IRIS OR Relapse	5 of 229	9 of 231	460	NCT01802385	Trial comparisons
Sertraline 400mg vs Placebo: Count of Participants With Cerebrospinal Fluid Sterility	101 of 229	90 of 231	460	NCT01802385	Trial comparisons
Sertraline 400mg vs Placebo: Event Free Survival	103 of 229	116 of 231	460	NCT01802385	Trial comparisons
Sertraline 400mg vs Placebo: Survival	109 of 229	125 of 231	460	NCT01802385	Trial comparisons
Sertraline 400mg vs Placebo: deaths from any cause	120 of 229	106 of 231	460	NCT01802385	Trial comparisons
Sertraline 400mg vs Placebo: serious adverse events	141 of 229	121 of 231	460	NCT01802385	Trial comparisons
Low Dose Flucytosine vs Control: Mortality	11 of 48	50 of 171	219	NCT06414512	Trial comparisons
Low Dose Flucytosine vs Control: deaths from any cause	11 of 48	50 of 171	219	NCT06414512	Trial comparisons
Low Dose Flucytosine vs Control: serious adverse events	31 of 48	132 of 171	219	NCT06414512	Trial comparisons
Low Dose Flucytosine vs Control: CSF Culture Sterility	25 of 44	60 of 97	141	NCT06414512	Trial comparisons

1 to 10 of 12

See all 12 comparisons in its trials

Papers from its trials23

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31345462	RESULT	1	PubMed
19897055	RESULT	1	PubMed
19441980	RESULT	1	PubMed
40795226	DERIVED	1	PubMed
40665233	DERIVED	1	PubMed
39972326	DERIVED	2	PubMed
39044381	DERIVED	1	PubMed
38943665	DERIVED	1	PubMed
38152404	DERIVED	1	PubMed
37606364	DERIVED	1	PubMed

1 to 10 of 23

See all 23 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005723

GET https://conductscience.org/api/diseases/v1/MONDO_0005723/trials?page=2

API reference For AI assistants